Gravity Analytica

Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13

TSHA 11.06.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-13

Name of Upcoming Event:Corporate Update Conference Call

Full Press Release SEC Filings Our TSHA Tweets

About Gravity Analytica

Recent Filings

DALLAS,Nov. 06, 2024(GLOBE NEWSWIRE) --Taysha Gene Therapies, Inc.(Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter endedSeptember 30, 2024, and host a corporate update conference call and webcast onWednesday, November 13, 2024, at4:30 PM Eastern Time.

Conference Call DetailsWednesday, November 13, at 4:30 PM Eastern Time / 3:30 PM Central TimeToll Free: 877-407-0792International: 201-689-8263Conference ID: 13748703Webcast:https://ir.tayshagtx.com/news-events/events-presentations

AboutTaysha Gene TherapiesTaysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visithttp://www.tayshagtx.com.

Company Contact:Hayleigh CollinsDirector, Head of Corporate Communications and Investor RelationsTaysha Gene Therapies, Inc.hcollins@tayshagtx.com

Media Contact:Carolyn HawleyInizio Evokecarolyn.hawley@inizioevoke.com

Source: Taysha Gene Therapies, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com